Antibody production: polyclonal-derived biotherapeutics.

Antibody based therapies using monoclonal or polyclonal antibodies are emerging as an important therapeutic approach for the treatment of a number of diseases. With increasing emphasis on new technologies associated with monoclonal antibody expression and purification, the clinical need of polyclonal therapeutics for treatment of a variety of specific illnesses and infections is often overlooked. Despite being largely abandoned in the early twentieth century due to the development of antibiotics, polyclonal antibody therapeutics are today widely used in medicine for viral and toxin neutralization and for replacement therapy in patients with immunoglobulin deficiencies. Over the past 20 years, intravenous immunoglobulins have shown beneficial immunomodulatory and anti-inflammatory effects in many illnesses. Hyperimmune antibody preparations have been used over the past century for the treatment of a variety of infectious agents and medical emergencies, including digoxin toxicity, snake envenomation and spider bites. Here, we examine the contemporary techniques and applications, and assess the future therapeutic potential, for polyclonal-derived antibody therapeutics.

[1]  B. Osborne,et al.  Cloned transchromosomic calves producing human immunoglobulin , 2002, Nature Biotechnology.

[2]  J. Hancox,et al.  Venomous snakebites in the United States: management review and update. , 2002, American family physician.

[3]  C. Tacket,et al.  Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. , 1984, The American journal of medicine.

[4]  Great Britain. Medicines Control Agency,et al.  Rules and guidance for pharmaceutical manufacturers and distributors 2002 , 2002 .

[5]  S. Bregenholt,et al.  Pathogen-specific recombinant human polyclonal antibodies: biodefence applications , 2004, Expert opinion on biological therapy.

[6]  R. Lemieux,et al.  Therapeutic intravenous immunoglobulins. , 2005, Molecular immunology.

[7]  N. Slater,et al.  Facile F(ab′)2 Manufacturing: Strategies for the Production of Snake Antivenoms , 2002 .

[8]  J. Sharon,et al.  Recombinant polyclonal antibodies for cancer therapy , 2005, Journal of cellular biochemistry.

[9]  A. Casadevall,et al.  Serum therapy revisited: animal models of infection and development of passive antibody therapy , 1994, Antimicrobial Agents and Chemotherapy.

[11]  T. D. Martin.  IGIV: contents, properties, and methods of industrial production--evolving closer to a more physiologic product. , 2006, International immunopharmacology.

[12]  A. Buchacher,et al.  Purification of intravenous immunoglobulin G from human plasma – aspects of yield and virus safety , 2006, Biotechnology journal.

[13]  S. Rosenberg,et al.  Passive immunotherapy of cancer in animals and man. , 1977, Advances in cancer research.

[14]  V. Wahn,et al.  Immunoglobulin Replacement Therapy in Primary Antibody Deficiency Diseases – Maximizing Success , 2005, International Archives of Allergy and Immunology.

[15]  I. Ishida,et al.  Artificial chromosome vectors and expression of complex proteins in transgenic animals. , 2003, Theriogenology.

[16]  J. Huggins,et al.  Use of intravenous immunoglobulin G (IVIG). , 2006, Best practice & research. Clinical haematology.

[17]  W. Sewell,et al.  Clinical uses of intravenous immunoglobulin , 2005, Clinical and experimental immunology.

[18]  C. Hanlon,et al.  Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. , 2003, The Journal of infectious diseases.

[19]  R. Hoffman,et al.  Efficacy of Crotalidae polyvalent antivenin for the treatment of hognosed viper (Porthidium nasutum) envenomation. , 2003, Annals of emergency medicine.

[20]  R. Clark,et al.  Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. , 2002, Annals of emergency medicine.

[21]  A. Casadevall.  Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons , 2002, Emerging infectious diseases.

[22]  T. Smith,et al.  Review of clinical experience with digoxin immune Fab (ovine). , 1991, The American journal of emergency medicine.

[23]  A. Casadevall,et al.  Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  A. Casadevall,et al.  The potential of antibody-mediated immunity in the defence against biological weapons , 2005, Expert opinion on biological therapy.

[25]  Kurt Brorson,et al.  The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. , 2005, Current opinion in biotechnology.

[26]  R. Clark,et al.  Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning. , 1997, Annals of emergency medicine.

[27]  M. Ballow.  Clinical and investigational considerations for the use of IGIV therapy. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[28]  G. Currie.  Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. , 1972, British Journal of Cancer.

[29]  R. Gallo,et al.  Anti-cytokine Ab immune therapy: present status and perspectives. , 2004, Drug discovery today.

[30]  A. Lihme,et al.  Capture of human Fab fragments by expanded bed adsorption with a mixed mode adsorbent , 1999, Bioseparation.